Skip to content Skip to footer
Subscribe Now
Viewpoints_Jason Lerner
VIEWPOINTS

Transcending Epilepsy Care: Jason Lerner from Biohaven in an Enlightening Dialogue Exchange with PharmaShots

Shots: Epilepsy affects around 1.5 million people in the US and 50 million globally. With approximately 40% of epilepsy patients being drug-resistant, there is an urgent need for innovative therapies Today, at PharmaShots we have Dr. Jason Lerner from Biohaven shedding light on BHV-7000, an investigational anti-seizure treatment and selective activator of potassium channels in…
November 6, 2024

Read more

Viewpoints_Fred Aslan
VIEWPOINTS

Enhancing Care with NK Cell Therapy: Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots

Shots: Immune reset in oncology has been observed with approved autologous CAR-T products. A recent study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases Today, at PharmaShots, we have Fred Aslan shedding light on Artiva's AlloNK,…
November 4, 2024

Read more

Viewpoints_Adityo Prakash
VIEWPOINTS

AI in Drug Discovery: Adityo Prakash from Verseon in an Illuminating Dialogue Exchange with PharmaShots

Shots: AI is widely used in drug discovery and clinical research to find innovative cures for several debilitating conditions with unmet healthcare needs Most of the AI architecture employs deep learning that requires extensive training data sets to produce reliable predictive models Today, at PharmaShots, we have Adityo Prakash, CEO of Verseon, addressing the challenges…
October 30, 2024

Read more

New Drug Designations - September 2024
INSIGHTS+

New Drug Designations – September 2024

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA, Health Canada and EMA. The September 2024 report covers regulatory designations for 42 drugs and 1 device, including 16 small molecules, 6 biologics, 12 cell and gene therapies, and 1 device, among others. Significant trends this month…
October 29, 2024

Read more

Viewpoints_Mina Makar
VIEWPOINTS

AstraZeneca at ERA’24: Mina Makar in a Stimulating Conversation with PharmaShots

Shots: Recently, AstraZeneca presented findings from the real-world IMPACT CKD study, which evaluated the multifaceted impact of CKD on patients, healthcare systems, and broader society, projecting future implications through 2032. The study emphasizes the importance of mitigating the economic burden on healthcare by implementing early, targeted screening, diagnosis, and treatment for CKD. In collaboration with…
October 28, 2024

Read more

Viewpoints_Baldo Scassellati Sforzolini
VIEWPOINTS

Unlocking Approval: Baldo Scassellati Sforzolini from Galderma in a Stimulating Dialogue Exchange with PharmaShots

Shots: Galderma’s Nemluvio (nemolizumab) was recently approved by the US FDA for the treatment of adults with prurigo nodularis, following positive Phase III results from the OLYMPIA study. Today at PharmaShots, we have Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma, to discuss the study’s design and the potential of Nemluvio in…
October 23, 2024

Read more

Viewpoints_Mark Mikhael
VIEWPOINTS

Enhancing Accessibility: Mark Mikhael from Olympia Pharmaceuticals in a Riveting Conversation with PharmaShots

Shots: Compounding pharmacies can help significantly by providing customized medications tailored to individual patient needs, bridging the gap in medicine delivery during a drug shortage, and enhancing accessibility.  Today, at PharmaShots, we have Mark Mikhael, CEO of Olympia Pharmaceuticals, an FDA-registered 503B outsourcing facility. Currently licensed in 47 states of the US, Olympia hosts two…
October 21, 2024

Read more

Viewpoints_Yelak Biru
VIEWPOINTS

Fund Raising Initiative: Yelak Biru from International Myeloma Foundation in Conversation with PharmaShots

Shots:  As a fund-raising initiative, the International Myeloma Foundation began a 3-day, 2-night cycling expedition from Aug 29thto Sep 3rd The initiative supports patient education, advocacy, and next-gen research to advance a cure for multiple myeloma Today, at PharmaShots we have Yelak Biru, President and CEO of the International Myeloma Foundation, shedding light on this…
October 16, 2024

Read more

Viewpoints_Stella Sarraf
VIEWPOINTS

Enhancing Neurodegenerative Care: Stella Sarraf from Spinogenix in an Enlightening Dialogue Exchange with PharmaShots

Shots: With a broad portfolio of candidates in ALS, Alzheimer’s disease, Schizophrenia, and Fragile X Syndrome, Spinogenix initiated the P-II study evaluating SPG302 for the treatment of patients with Alzheimer’s disease SPG302, a synaptic regenerative therapy, is aimed to provide an effective and patient-friendly solution as a daily pill for ALS and Alzheimer’s disease Today…
October 14, 2024

Read more

Load more